340B stakeholders urged U.S. Senate Finance Committee Democrats to consider competing drug pricing policy priorities in response to an RFI.

U.S. Senate Finance Committee Dems’ Drug Pricing RFI Sparks 340B Comments

August 20, 2026 Luke Zarzecki, National Correspondent 340B Report Views

Drug industry stakeholders recently asked Democrats on a key U.S. Senate committee to consider 340B program reforms as part of [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!